Quick Answer
BeOne Medicines Ltd. reported Long-Term Debt of $961.91 million for fiscal year 2025.
BeOne Medicines Ltd. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $961.91M | +477.8% |
| 2024 | $166.48M | -15.8% |
| 2023 | $197.62M | -86.3% |
| 2022 | $1.44B | +12.0% |
| 2021 | $1.29B | +601.4% |
| 2020 | $183.64M | -68.3% |
| 2019 | $580.00M | +1322.1% |
| 2018 | $40.78M | +342.3% |
| 2017 | $9.22M | -46.6% |
| 2016 | $17.28M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $146.09M | -89.1% | -8.8% |
| March 31, 2025 | $160.16M | -19.5% | -3.8% |
| December 31, 2024 | $166.48M | -15.8% | -87.3% |
| September 30, 2024 | $1.32B | -11.0% | -2.3% |
| June 30, 2024 | $1.35B | -10.5% | +576.5% |
| March 31, 2024 | $199.03M | -86.0% | +0.7% |
| December 31, 2023 | $197.62M | -5.5% | -86.6% |
| September 30, 2023 | $1.48B | -0.1% | -1.7% |
- BeOne Medicines Ltd. showed an increase of +477.8% in Long-Term Debt compared to the prior fiscal year.
- Over the 2016–2025 period, BeOne Medicines Ltd.’s long-term debt has grown by 5465.3% (from $17.28 million to $961.91 million).
- The most recent figure is from BeOne Medicines Ltd.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: